CareDx (CDNA) Receives Buy Rating from Craig Hallum
Craig Hallum restated their buy rating on shares of CareDx (NASDAQ:CDNA) in a research report released on Friday morning, The Fly reports. They currently have a $40.00 target price on the stock.
CDNA has been the topic of a number of other reports. BidaskClub raised shares of CareDx from a buy rating to a strong-buy rating in a report on Tuesday, August 14th. Zacks Investment Research downgraded shares of CareDx from a buy rating to a sell rating in a report on Wednesday, August 15th. Raymond James reaffirmed a strong-buy rating and set a $30.00 price objective on shares of CareDx in a report on Tuesday, October 23rd. HC Wainwright reaffirmed a neutral rating and set a $22.00 price objective on shares of CareDx in a report on Tuesday, September 18th. Finally, Piper Jaffray Companies lifted their price objective on shares of CareDx to $42.00 in a report on Wednesday, September 5th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and three have given a strong buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $29.60.
CDNA traded down $2.13 during mid-day trading on Friday, reaching $25.61. 2,159,992 shares of the stock were exchanged, compared to its average volume of 643,702. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.16 and a quick ratio of 1.83. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -33.26 and a beta of 1.06. CareDx has a 1 year low of $4.92 and a 1 year high of $30.15.
In related news, CFO Michael Brian Bell sold 12,500 shares of the business’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $16.84, for a total value of $210,500.00. Following the transaction, the chief financial officer now directly owns 68,593 shares of the company’s stock, valued at approximately $1,155,106.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Neil Gagnon sold 108,599 shares of the business’s stock in a transaction dated Wednesday, October 31st. The stock was sold at an average price of $27.05, for a total transaction of $2,937,602.95. The disclosure for this sale can be found here. Insiders sold a total of 163,954 shares of company stock worth $4,187,359 over the last three months. 3.40% of the stock is owned by insiders.
Several large investors have recently modified their holdings of the stock. Fred Alger Management Inc. boosted its holdings in shares of CareDx by 61.4% in the 2nd quarter. Fred Alger Management Inc. now owns 3,262,790 shares of the company’s stock worth $39,937,000 after buying an additional 1,241,668 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of CareDx by 3.0% in the 3rd quarter. BlackRock Inc. now owns 2,328,861 shares of the company’s stock worth $67,187,000 after buying an additional 67,556 shares during the last quarter. Gagnon Securities LLC boosted its holdings in shares of CareDx by 9.5% in the 2nd quarter. Gagnon Securities LLC now owns 1,960,025 shares of the company’s stock worth $23,991,000 after buying an additional 170,673 shares during the last quarter. Gagnon Advisors LLC boosted its holdings in shares of CareDx by 1.1% in the 2nd quarter. Gagnon Advisors LLC now owns 965,894 shares of the company’s stock worth $11,823,000 after buying an additional 10,136 shares during the last quarter. Finally, RTW Investments LP boosted its holdings in shares of CareDx by 36.4% in the 2nd quarter. RTW Investments LP now owns 764,532 shares of the company’s stock worth $9,358,000 after buying an additional 203,932 shares during the last quarter. 74.63% of the stock is currently owned by institutional investors.
CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics.
Featured Story: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.